In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L

Li, Jiyang; Huang, Hai; Feng, Meiqing; Zhou, Wei; Shi, Xunlong; Zhou, Pei

doi:10.1016/j.antiviral.2008.03.001

Cited by 57 publications

(43 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis B virus (HBV), a member of the hepadnavirus (hepatotropic DNA virus) family, 1 has caused a global health crisis as the ninth leading cause of death in the world by chronically infecting more than 400 million people according to the World Health Organization (WHO). 2 HBV is a fatal disease epidemic in Southeast Asia, Africa and China, where approximately 10% of the populations are chronic carriers.…”

Section: Introductionmentioning

confidence: 99%

Cluster Analysis and QSAR Study of Some Anti‐hepatitis B Virus Agents Comprising 4‐Aryl‐6‐chloro‐quinolin‐2‐ones and 5‐Aryl‐7‐chloro‐1,4‐benzodiazepines

Chen

Xie

et al. 2009

Chin. J. Chem.

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection has caused a global health crisis by infecting more than 400 million people, constituting the ninth leading cause of death in the world. There is an urgent demand for antiviral agents to effectively inhibit HBV infection based on the development of drug resistance and increasing infected numbers. Quantitative structure-activity relationship (QSAR) models were developed for a series of potent anti-hepatitis B virus agents comprising 4-aryl-6-chloro-quinolin-2-ones and 5-aryl-7-chloro-1,4-benzodiazepines using Cerius r ＝0.989) constructed by the genetic function approximation (GFA) methodology indicates that the activity was mainly governed by E-State-keys (S_sssN and S_sCl), electronic descriptor (LUMO), thermodynamic descriptor (Foct) and conformational descriptor (Energy). 3D-QSAR models were developed based on steric and electrostatic interactions by molecular field analysis (MFA) to investigate the substitutional requirements for the favorable receptor-drug interaction, showing that electrostatic interactions is crucial for the activity. The models derived can provide a preliminary valuable guidance for continuing search for novel potent anti-hepatitis B virus agents prior to synthesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Cluster Analysis and QSAR Study of Some Anti‐hepatitis B Virus Agents Comprising 4‐Aryl‐6‐chloro‐quinolin‐2‐ones and 5‐Aryl‐7‐chloro‐1,4‐benzodiazepines

Chen

Xie

et al. 2009

Chin. J. Chem.

View full text Add to dashboard Cite

show abstract

“…Measurement of HBsAg and HBeAg: Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in the supernatant was quantified after 9 days of culture in the presence or absence of OAG and baicalin 22 [16]. The concentration of HBsAg or HBeAg was measured by an enzyme-linked immunosorbent assay (ELISA) kit following the manufacturer's protocol.…”

Section: Anti-hbv Testmentioning

confidence: 99%

“…The HBVDNA copy number was normalized to GAPDH and calculated by the iQTM Real-Time System software (Version 3.0 for windows, BIORAD, USA). HBV DNA inhibition rate (%)=(copy number of the control−copy number of the study sample)/ copy number of the control × 100% [22].…”

Section: Anti-hbv Testmentioning

confidence: 99%

See 1 more Smart Citation

In vitro Broad Antiviral Function against HBV, HSV, H3N2 Replication by Baicalin and Oroxylin A-7-O-Β-D-Glucoside

An¹,

Li²,

Guan³

et al. 2017

Virol Mycol

Self Cite

View full text Add to dashboard Cite

Flavonoids have been previously shown to possess anti-viral activities In vitro. Oroxylin A-7-O-β-D-glucoside (OAG), a flavonoids produced by microbial conversion, and its substrate baicalin, were assayed for antiviral function against hepatitis B virus (HBV), herpes simplex virus type 2 (HSV-2) and influenza A virus (H3N2). Incubation with 100 μg/ml OAG or baicalin for 9 days reduced human HBV-transfected liver cell line HepG2 2.2.15 secretion of Hepatitis B surface antigen (HBsAg) by 83.17%, and 47.175%, respectively, and Hepatitis B e antigen (HBeAg) by 27.35%, 25.56% respectively.OAG and baicalin inhibited HSV-II-induced cell death in a concentration dependent manner (ranging from by 75% and 62.5%, respectively at 12.5 μg/ml and 50%, 37.5%, respectively at 6.25 μg/ml). OAG (100 μg/ml) and biacalin (50 μg/ml) also effectively inhibited H3N2-induced toxicity in MDCK by 62.5% and 50%, respectively. In summary, OAG and baicalin could inhibit several viruses In vitro and OAG was more potent than baicalin. OAG may represent a candidate antiviral with broad activity against HBV, HSV-2 and H3N2 infection.

show abstract

“…On day 3, 6, and 9 of drug treatment, HBsAg and HBeAg in the cell culture supernatant were detected using a commercially available ELISA kit (Kehua Bio-engineering Corporation, Shanghai, China) according to the manufacturer's protocol (21). Inhibition rates (%) were calculated using the following formula: [1 -(A450/630 of experimental group / A450/630 of negative control) × 100%] (22).…”

Section: Detection Of Hbsag and Hbeag In The Culture Supernatantmentioning

confidence: 99%

Anti-hepatitis B Virus Activity of α-DDB-FNCG, a Novel Nucleoside-Biphenyldicarboxylate Compound In Vitro and In Vivo

Yang

Zhao

et al. 2014

J Pharmacol Sci

View full text Add to dashboard Cite

Abstract.A novel codrug, a-DDB-FNCG, was synthesized through coupling of a-biphenyl dimethyl dicarboxylate (a-DDB) and the nucleoside analogue FNCG, via an ester bond. The anti-HBV activity and hepatoprotective effects of this compound were investigated both in vitro and in vivo. In HBV-transfected HepG2.2.15 cell line, the secretion of HBsAg and HBeAg as well as the levels of extracellular and intracellular viral DNA were determined by ELISA and real-time fluorescent quantitative Polymerase Chain Reaction (FQ-PCR), respectively. In DHBV-infected ducks, the viral DNA levels in serum and liver were determined by FQ-PCR. In addition, the levels of alanine transaminase (ALT) and aspartate aminotransferase (AST) in both serum and liver were also examined. The improvement of ducks' livers was evaluated by histopathological analysis. It has been demonstrated that a-DDB-FNCG could suppress the levels of HBV antigens and viral DNA in a time-and dose-dependent manner in the HepG2.2.15 cell line. Furthermore, this codrug could also significantly inhibit the viral DNA replication and reduce the ALT and AST levels in both serum and liver of DHBV-infected ducks, with improved hepatocellular architecture in drugtreated ducks. In short, these results suggest that a-DDB-FNCG could be a promising candidate for further development of new anti-HBV agents with hepatoprotective effects.

show abstract

In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L

Cited by 57 publications

References 14 publications

Cluster Analysis and QSAR Study of Some Anti‐hepatitis B Virus Agents Comprising 4‐Aryl‐6‐chloro‐quinolin‐2‐ones and 5‐Aryl‐7‐chloro‐1,4‐benzodiazepines

Cluster Analysis and QSAR Study of Some Anti‐hepatitis B Virus Agents Comprising 4‐Aryl‐6‐chloro‐quinolin‐2‐ones and 5‐Aryl‐7‐chloro‐1,4‐benzodiazepines

In vitro Broad Antiviral Function against HBV, HSV, H3N2 Replication by Baicalin and Oroxylin A-7-O-Β-D-Glucoside

Anti-hepatitis B Virus Activity of α-DDB-FNCG, a Novel Nucleoside-Biphenyldicarboxylate Compound In Vitro and In Vivo

Contact Info

Product

Resources

About